Active material: Betametazon, Fusidic acid
When ATH: D07CC01
CCF: Drug with antibacterial and anti-inflammatory for outdoor use
ICD-10 codes (testimony): L20.8, L21, L23, L24, L28.0, L93.0
When CSF: 04.05

Pharmaceutical form, composition and packaging

Cream for external application uniform, white.

1 g
fusidic acid micronized (based on the anhydrous acid)20 mg
ʙetametazon valerat (based on betamethasone)1 mg

Excipients: macrogol cetostearyl ether, cetostearyl alcohol, chlorocresol, sodium dihydrogen phosphate dihydrate, Liquid paraffin, white soft paraffin, Sodium hydroxide, Purified water.

15 g – aluminum tuba (1) – packs cardboard.


Pharmacological action

Combined preparation for external use, protivozudnoedeystvie combines anti-inflammatory and antimicrobial effects of betamethasone with fusidic acid.

Highly active against Staphylococcus spp., especially Staphylococcus aureus and Staphylococcus epidermidis (including methicillin-resistant strains), Streptococcus spp., Neisseria spp., Clostridium spp., Nocardia asteroids, Enterococcus spp., Bacteroides spp., Mycobacterium tuberculosis, Mycobacterium leprae и Corynebacterium minute.

The antibacterial activity of fusidic acid is not reduced in the presence of betamethasone.



For external use of the drug into the skin gets around 2%, low systemic absorption.



Dermatitis in the presence of a bacterial infection or suspected it:

- Atopic dermatitis;

- Seborrheic dermatitis;

- A simple contact dermatitis;

- Allergic dermatitis;

- Eczema;

- Chronic zoster;

- Red discoid lupus.


Dosage regimen

Futsikort cream applied to the affected area of ​​the skin with a thin layer 2 times / day. A course of treatment - 2 of the week.


Side effect

Dermatological reactions: 1-2% (As with other glucocorticosteroids) – itch, burning, redness, pricking, xerosis, and irritation, rash; rarely – aknepodobnye changes, gipopigmentatsiya, folliculitis, striae, skin atrophy, hypertryhoz, contact type allergy.

Side-effects when applied externally are rare, and are reversible.

In case of hypersensitivity reactions or side effects therapy should be discontinued.



- Lupus;

- Cutaneous manifestations of syphilis;

- Enable vetryanaya;

- Viral and fungal infections of the skin;

- Skin reactions after vaccination;

- Open wounds;

- Sores;

- Rosacea;

- Acne vulgaris;

- Hypersensitivity to the drug.


Pregnancy and lactation

Since the clinical studies of the drug during pregnancy and lactation have not been conducted, formulation should not be used in pregnancy in high doses and for a long time; lactation (breast-feeding) the drug should not be applied on the breast.

IN experimental studies found, Futsikort that does not have embryotoxic and teratogenic.

For external use Futsikorta selection as fusidic acid, and betamethasone in breast milk is unlikely due to the low systemic absorption.



Avoid prolonged use of the drug, particularly on the face and skin folds and, especially in children, due to the risk of suppression of adrenal function.

Should not cause the drug to the eye (because of the possible development of glaucoma and cataracts), and wound on the surface and mucous membranes.



Exceeding the recommended dose, long-term use of topical corticosteroids on the vast surface of the skin can lead to the suppression of the hypothalamic-pituitary-adrenal system and the development of symptoms of Cushing.

Treatment: It recommended a gradual withdrawal of the drug, simptomaticheskaya therapy; If necessary, a correction of electrolyte imbalance.


Drug Interactions

Drug drug interactions are not described Futsikort.


Conditions of supply of pharmacies

The drug is released under the prescription.


Conditions and terms

The drug should be stored out of reach of children at or above 25 ° C. Shelf life 3 year.

Back to top button